The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...

The biotech company Dynamic42, a specialist in organ-on-chip technology, has made a significant advance in pancreatic cancer ...

Dr. Marty Makary, President Trump's pick to run the Food and Drug Administration, faced questions from the Senate HELP ...

Professor Teusch and Dynamic42 set out their work in one of the most challenging cancers, with PDAC being the most common and lethal form of pancreatic cancer. A major cause of it ...

Dr. Marty Makary will testify before the Senate health committee on Thursday. Lawmakers may press him over staff reductions ...

The statement unites the cancer community in opposing recent executive actions and calling on both the administration and ...

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

A new assay rapidly detected pancreatic ductal adenocarcinoma and differentiated it from noncancer pancreatic diseases by ...

A multidisciplinary team of University of Cincinnati Cancer Center researchers ... in human trials in the UK and Europe. The U.S. Food and Drug Administration (FDA) has approved vimseltinib ...

Scientists at Oregon Health and Science University (OHSU) have developed a new blood test for pancreatic cancer, one of the most deadly forms of the disease. Tests showed up to 85% accuracy in ...